Project Grant HT94252410564
Award Date 9/1/24
Completion Date 8/31/27
Dollars Obligated $948K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The federal Project Grant award of $711,821.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Dana-Farber Cancer Institute, Inc. (DFCI) on the "Molecular Pathways of Uveal Melanoma Dormancy" from October 1, 2025 to September 30, 2027. As a leading academic medical research institution, DFCI will leverage its expertise in oncology, immunology, molecular biology, and precision medicine to advance the...
- The Department of Defense's Defense Health Agency awarded a $820,833 Project Grant to The Schepens Eye Research Institute, Inc., a non-profit research organization affiliated with Harvard Medical School and Massachusetts Eye and Ear. The grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports a research project to "Identify the Liver Microenvironment that Drives Uveal Melanoma Metastasis and Immunity." The 3-year award, effective from...
- The U.S. Defense Health Agency awarded a $538,596 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "IDENTIFICATION OF THE LIVER MICROENVIRONMENT THAT DRIVES UVEAL MELANOMA METASTASIS AND IMMUNITY". The project aims to advance scientific understanding of the liver microenvironment and how it contributes to the metastasis and immune response related to uveal melanoma, a rare and...
- The federal Project Grant award in the amount of $178,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is funding research at the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts to target the Merkel ST-MYCL-EP400 complex in Merkel cell carcinoma. The research aims to develop innovative approaches to the understanding, detection, and treatment of this rare and aggressive form of skin cancer...
- The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $302,228 project grant to The Regents of the University of California, San Francisco to support research on "Establishing and Overcoming the Mechanisms of Liver Metastasis-Induced Systemic Tumor Immune Tolerance and Immunotherapy Resistance in Melanoma." The 3-year grant project, running from September 30, 2023 to September 29, 2026, will investigate the biological mechanisms by...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
- The U.S. Defense Health Agency awarded Yale University a $912,487 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on the role of Polycomb Repressive Complex 1 in the progression of uveal melanoma. The 3-year research project, starting on September 15, 2023 and ending on September 14, 2026, aims to advance the understanding of this specific protein complex's involvement in the development and spread of a rare form...
- This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $959,882.00 to The Regents of the University of California, San Francisco (UCSF) to establish and overcome the mechanisms of liver metastasis-induced systemic tumor immune tolerance and immunotherapy resistance in melanoma. The 3-year research project aims to investigate fundamental biological processes and develop new therapeutic approaches to enhance the...